Your session is about to expire
← Back to Search
Duloxetine + Neurofeedback for Peripheral Neuropathy
Study Summary
This trial is testing whether duloxetine and neurofeedback training can help relieve symptoms of chemotherapy-induced peripheral neuropathy better than duloxetine or neurofeedback training alone.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My pain level is 4 or higher, or I have nerve pain rated from mild to severe.I am on hormonal or targeted cancer therapies and can continue them during the study.I have been diagnosed with bipolar disorder or schizophrenia.I am currently taking antipsychotic medication.I am aware of any reasons I shouldn't receive DL treatment.I can attend therapy at the cancer center, live close enough for home visits, or can go to a regional care center.I haven't had chemotherapy in the last 3 months.I do not have active brain metastases or severe brain disorders.My nerve pain is due to chemotherapy, as confirmed by my doctor.I have nerve damage not caused by chemotherapy.I am currently taking duloxetine for nerve pain.I have thoughts of harming myself.I can take care of myself and am up and about more than half of the day.I have had nerve pain symptoms for at least 3 months.I have had a head injury or seizures in the past.
- Group 1: Group II (neurofeedback training)
- Group 2: Group I (neurofeedback training, duloxetine)
- Group 3: Group III (duloxetine)
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What findings have been made in other research projects that also looked at Duloxetine?
"Currently, 26 separate clinical trials are ongoing to research duloxetine. Out of these, 4 have reached Phase 3. Trials for duloxetine are being conducted at 786 different locations with a large concentration in Redwood City, California."
What are the most popular indications for Duloxetine?
"Duloxetine is an effective medication for treating diabetic peripheral neuropathy, knee pain, and major depressive disorder."
How large is the patient sample size for this clinical trial?
"That is correct, the listing on clinicaltrials.gov demonstrates that this study is still recruiting participants. The trial was first posted on 7/10/2020 and was last updated on 10/6/2022. There are plans to enroll 380 patients at 2 locations."
Are researchers looking for more participants in this clinical trial?
"Yes, the information on clinicaltrials.gov point out that this study is actively recruiting patients. The study was first posted on 7/10/2020 and was last updated on 10/6/2022. The clinical trial is looking for 380 participants between 2 sites."
What are some of the dangers associated with taking Duloxetine?
"Duloxetine, for which this is a Phase 2 trial meaning that while there is some safety data it has yet to be proven effective, received a score of 2."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger